BridgeBio presents data from ATTRibute-CM study on acoramidis

BridgeBio (BBIO) Pharma presented data from the ATTRibute-CM study, showing that acoramidis significantly reduces all-cause mortality, ACM, through Month 42 in the overall variant ATTR-CM population, and specifically in the p.Val142Ile subpopulation. The V142I variant disproportionately affects individuals of Western African ancestry, with a carrier frequency of 3-4% in the U.S. Black population. These data were presented in two moderated digital posters at the American Heart Association, AHA, Scientific Sessions 2025 and were simultaneously published in JAMA Cardiology. These results in the variant and V142I subpopulations are consistent with the statistically significant results previously presented from the ATTRibute-CM study in the wild-type population, and the ATTR-CM population overall. Acoramidis is a selective, small molecule, orally administered, near-complete transthyretin stabilizer.